Adenoviral vectors: systemic delivery and tumor targeting.
The development of a targeted adenoviral vector, which can be delivered systemically, is one of the major challenges facing cancer gene therapy. The virus is readily cleared from the bloodstream, can be neutralised by pre-existing antibodies, and has a permissive cellular tropism. Clinical studies using the ONYX virus have shown limited efficacy, but there are several hurdles to overcome to achieve an effective tumor-specific systemic therapy. In this review, we have summarized the various strategies used to overcome the limitations of adenoviral-mediated gene delivery.
Green
Nicola K
NK
Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, UK. nicky.green@clinpharm.ox.ac.uk
Seymour
Leonard W
LW
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002986:Clinical Trials as Topic; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors / Q000235:genetics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy* / Q000821:virology; D009928:Organ Specificity; D011401:Promoter Regions, Genetic; D014018:Tissue Distribution; D014779:Virus Replication / Q000502:physiology